Overview

Nonalcoholic fatty liver disease, often called NAFLD, is a liver problem that affects people who drink little to no alcohol. In NAFLD, too much fat builds up in the liver. It is seen most often in people who are overweight or obese.

NAFLD is becoming more common, especially in Middle Eastern and Western nations as the number of people with obesity rises. It is the most common form of liver disease in the world. NAFLD ranges in severity from hepatic steatosis, called fatty liver, to a more severe form of disease called nonalcoholic steatohepatitis (NASH).

NASH causes the liver to swell and become damaged due to the fat deposits in the liver. NASH may get worse and may lead to serious liver scarring, called cirrhosis, and even liver cancer. This damage is like the damage caused by heavy alcohol use.

A move is currently underway to change the name nonalcoholic fatty liver disease to metabolic dysfunction-associated steatotic liver disease (MASLD). Experts also have recommended changing the name nonalcoholic steatohepatitis to metabolic dysfunction-associated steatohepatitis (MASH).

Symptoms

NAFLD often has no symptoms. When it does, they may include:

  • Fatigue.
  • Not feeling well, or malaise.
  • Pain or discomfort in the upper right belly area.

Possible symptoms of NASH and cirrhosis, or severe scarring, include:

  • Itchy skin.
  • Abdominal swelling, also called ascites (uh-SY-teez).
  • Shortness of breath.
  • Swelling of the legs.
  • Spider-like blood vessels just beneath the skin's surface.
  • Enlarged spleen.
  • Red palms.
  • Yellowing of the skin and eyes, or jaundice.

When to see a doctor

Make an appointment with a member of your health care team if you have lasting symptoms that worry you.

Get the latest health information from Mayo Clinic delivered to your inbox.

Subscribe for free and receive your in-depth guide to digestive health, plus the latest on health innovations and news. You can unsubscribe at any time. Click here for an email preview.

To provide you with the most relevant and helpful information, and understand which information is beneficial, we may combine your email and website usage information with other information we have about you. If you are a Mayo Clinic patient, this could include protected health information. If we combine this information with your protected health information, we will treat all of that information as protected health information and will only use or disclose that information as set forth in our notice of privacy practices. You may opt-out of email communications at any time by clicking on the unsubscribe link in the e-mail.

Causes

Experts don't know exactly why fat builds up in some livers and not others. They also don't fully understand why some fatty livers turn into NASH.

NAFLD and NASH are both linked to the following:

  • Genetics.
  • Overweight or obesity.
  • Insulin resistance, which happens when your cells don't take up sugar in response to the hormone insulin.
  • Type 2 diabetes, sometimes called high blood sugar or hyperglycemia.
  • High levels of fats, especially triglycerides, in the blood.

These combined health problems may contribute to a fatty liver. However, some people get NAFLD even if they do not have any risk factors.

Risk factors

Many diseases and health problems can increase your risk of NAFLD, including:

  • Family history of fatty liver disease or obesity.
  • Growth hormone deficiency, which means the body doesn't make enough hormones to grow.
  • High cholesterol.
  • High levels of triglycerides in the blood.
  • Insulin resistance.
  • Metabolic syndrome.
  • Obesity, especially when fat is centered in the waist.
  • Polycystic ovary syndrome.
  • Obstructive sleep apnea.
  • Type 2 diabetes.
  • Underactive thyroid, also called hypothyroidism.
  • Underactive pituitary gland, or hypopituitarism.

NASH is more likely in these groups:

  • People older than 50.
  • People with certain genetic risk factors.
  • People with obesity.
  • People with diabetes or high blood sugar.
  • People with symptoms of metabolic syndrome, such as high blood pressure, high triglycerides and a large waist size.

It is hard to tell apart NAFLD from NASH without a clinical evaluation and testing.

Complications

Severe liver scarring, or cirrhosis, is the main complication of NAFLD and NASH. Cirrhosis happens because of liver injury, such as the damage caused by inflammation in NASH. As the liver tries to stop inflammation, it creates areas of scarring, also called fibrosis. With ongoing inflammation, fibrosis spreads and takes up more liver tissue.

If nothing is done to stop the scarring, cirrhosis can lead to:

  • Fluid buildup in the stomach area, called ascites.
  • Swollen veins in your esophagus, or esophageal varices, which can rupture and bleed.
  • Confusion, sleepiness and slurred speech, also called hepatic encephalopathy.
  • Overactive spleen, or hypersplenism, which can cause too few blood platelets.
  • Liver cancer.
  • End-stage liver failure, which means the liver has stopped working.

Experts guess that about 24% of adults in the U.S. have NAFLD, and about 1.5% to 6.5% have NASH.

Prevention

To reduce your risk of NAFLD:

  • Eat a healthy diet. Eat a healthy diet that's rich in fruits, vegetables, whole grains and healthy fats.
  • Limit alcohol, simple sugars and portion sizes. Avoid sugary drinks like soda, sports drinks, juices and sweet tea. Drinking alcohol can damage your liver and should be avoided or minimized.
  • Keep a healthy weight. If you are overweight or obese, work with your health care team to gradually lose weight. If you are a healthy weight, work to keep it by eating a healthy diet and exercising.
  • Exercise. Be active most days of the week. Get an OK from your health care team first if you haven't been exercising regularly.

April 04, 2024

Living with nonalcoholic fatty liver disease?

Connect with others like you for support and answers to your questions in the Transplants support group on Mayo Clinic Connect, a patient community.

Transplants Discussions

jolinda
Transplant anti-rejection medications. What's your advice?

371 Replies Mon, Dec 16, 2024

lmctif
Liver transplant - Let's support each other

1623 Replies Sun, Dec 15, 2024

See more discussions
  1. Cusi K, et al. American Association of Clinical Endocrinology clinical practice guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings: Co-sponsored by the American Association for the Study of Liver Diseases (AASLD). Endocrine Practice. 2022; doi:10.1016/j.eprac.2022.03.010.
  2. Nonalcoholic fatty liver disease (NAFLD). American Liver Foundation. https://liverfoundation.org/liver-diseases/fatty-liver-disease/nonalcoholic-fatty-liver-disease-nafld. Accessed May 11, 2023.
  3. Nonalcoholic fatty liver disease (NAFLD) and NASH. National Institute of Diabetes and Digestive and Kidney Diseases. https://www.niddk.nih.gov/health-information/liver-disease/nafld-nash. Accessed May 11, 2023.
  4. Sheth SG, et al., eds. Epidemiology, clinical features, and diagnosis of nonalcoholic fatty liver disease in adults. https://www.uptodate.com/contents/search. Accessed May 11, 2023.
  5. Elsevier Point of Care. Clinical Overview: Nonalcoholic fatty liver disease. https://www.clinicalkey.com. Accessed May 11, 2023.
  6. Chen YP, et al. A systemic review and a dose-response meta-analysis of coffee dose and nonalcoholic fatty liver disease. Clinical Nutrition. 2018. doi: 10.1016/j.clnu.2018.11.030.
  7. Ludwig J, et al. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clinic Proceedings. 1980;55:434.
  8. Nonalcoholic fatty liver disease (NAFLD). Merck Manual Professional Version. https://www.merckmanuals.com/professional/hepatic-and-biliary-disorders/approach-to-the-patient-with-liver-disease/nonalcoholic-fatty-liver-disease-nafld. Accessed May 11, 2023.
  9. Malhi H, et al. Nonalcoholic fatty liver: Optimizing pretransplant selection and posttransplant care to maximize survival. Current Opinion in Organ Transplantation. 2016. doi:10.1097/MOT.0000000000000283.
  10. Heimbach JK, et al. Combined liver transplantation and gastric sleeve resection for patients with medically complicated obesity and end-stage liver disease. American Journal of Transplantation. 2013. doi:10.1111/j.1600-6143.2012.04318.x.
  11. Cho JH, et al. The clinical and metabolic effects of intragastric balloon on morbid obesity and its related comorbidities. Clinical Endoscopy. 2021. doi: 10.5946/ce.2020.302.
  12. AskMayoExpert. Nonalcoholic fatty liver disease (adult). Mayo Clinic; 2022.
  13. Thomas RA. Allscripts EPSi. Mayo Clinic. May 25, 2023.
  14. Khanna, S (expert opinion). Mayo Clinic. June 20, 2023.
  15. Rinella ME, et al. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. Journal of Hepatology. 2023; doi:10.1016/j.jhep.2023.06.003.
  16. Rezdiffra (approval letter). New Drug Application 217785. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217785. Accessed March 29, 2024.
  17. Teng ML, et al. Global incidence and prevalence of nonalcoholic fatty liver disease. Clinical and Molecular Hepatology. 2023; doi:10.3350/cmh.2022.0365.

Related

Associated Procedures

News from Mayo Clinic

Products & Services